凯普生物 (300639)
Guangdong Hybribio Biotech Co.,Ltd.
K-Line Chart
No K-line data
Company NameGuangdong Hybribio Biotech Co., Ltd.
Listing Date2017-04-12
Issue Price18.39Yuan
Registered Capital64650.067410K Yuan
Legal RepresentativeGuan Qiaozhong
Registered AddressPlot D5-3-3-4, North Section High-Tech Zone, Economic Development and Experimental Zone, Chaozhou City, Guangdong Province
IndustryMedical Devices
Main BusinessResearch, development, production, and sales of in vitro diagnostic-related products such as molecular diagnostic reagents and supporting instruments.
Company ProfileGuangdong Hybribio Biotech Co., Ltd. is a leading domestic provider of nucleic acid molecular diagnostic products. Leveraging its superior independent innovation and R&D capabilities, Hybribio was recognized as a High-Tech Enterprise in 2008 and as a Guangdong Provincial Innovative Enterprise in 2012. In 2012, with approval from the Guangdong Provincial Department of Science and Technology, Development and Reform Commission, and Economic and Information Commission, the company established the 'Guangdong Provincial Engineering Technology Research and Development Center for Molecular Diagnosis of Human Papillomavirus (HPV)-Related Diseases,' becoming one of the few enterprises in China's molecular diagnostics field capable of establishing a provincial-level R&D center.
Stock Details
1. Key Indicators
- Total Shares(W): 64650.07
- Circulating A-Shares(W): 63516.44
- Earnings Per Share(RMB): -0.1996
- Net Assets Per Share(RMB): 5.9410
- Operating Revenue(W RMB): 48587.17
- Total Profit(W RMB): -17735.96
- Net Profit Attributable to Parent(W RMB): -12768.33
- Net Profit Growth Rate(%): 51.25
- Weighted Return on Equity(%): -3.2400
- Operating Cash Flow Per Share(RMB): 0.1880
- Undistributed Profit Per Share(RMB): 3.6125
- Capital Reserve Per Share(RMB): 1.1241
2. Main Business
The main business covers:
- Molecular diagnostic products
- Medical laboratory services
- Medical and health services
3. Company Basic Information
- Company Name: Guangdong Hybribio Biotech Co., Ltd.
- Listing Date: 2017-04-12
- Industry: Pharmaceutical Manufacturing
- Address: D5-3-3-4 District, North Section of High-tech Zone, Economic Development Experimental Zone, Chaozhou City, Guangdong Province
- Website: www.hybribio.cn
- Company Profile：The company's predecessor was Guangdong Hybribio Biotechnology Co., Ltd. (formerly known as Chaozhou Hybribio Bioinstrument Co., Ltd. and Guangdong Hybribio Bioinstrument Co., Ltd.), established on June 13, 2003. In December 2010, Hybribio Limited was restructured into a joint stock company based on the audited net assets of RMB 52,684,494.96 as of June 30, 2010, converted into 52 million shares at a ratio of 1:0.987007658, with a par value of RMB 1 per share. On December 31, 2010, the company completed the industrial and commercial change registration with the Chaozhou Administration for Industry and Commerce.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Technology Venture Co., Ltd. | General Legal Person | 19319.83 | 30.42 |
| 2 | Yunnan Zhonghe Zhi Enterprise Management Co., Ltd. | General Legal Person | 4014.76 | 6.32 |
| 3 | Shenzhen Guotiao Zhaoshang M&A Equity Investment Fund Partnership (Limited Partnership) | General Legal Person | 3076.57 | 4.84 |
| 4 | Yunnan Yanchen Enterprise Management Co., Ltd. | General Legal Person | 1463.75 | 2.30 |
| 5 | Yongwin CSI All Share Medical Devices Exchange Traded Open-End Index Securities Investment Fund | Fund | 239.20 | 0.38 |
| 6 | Hong Kong University Keqiao Co., Ltd. | General Legal Person | 131.87 | 0.21 |
5. Concept Sectors
- Private Hospital
- Gene Concept
- Artificial Intelligence
- Helicobacter Pylori
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- DeepSeek
- Margin Trading & Securities Lending
- Below Net Asset Value
- Consecutive Losses
- Intended Reduction
- Special Loans
- Micro & Small Cap Stocks
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information